Search Results

SYNTAX Analysis Studies Cost Effectiveness of Taxus Express²

SYNTAX Investigates Quality-of-Life Results of PCI

March 17, 2011—In The New England Journal of Medicine, David J. Cohen, MD, et al have published findings from the SYNTAX (Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial that investigated the quality-oflife effects of percutaneous coronary intervention (PCI) with the use of drug-eluting stents (2011;364:1016–1026). The SYNTAX study is sponsored by Boston Scientific Corporation (Natick, MA).

Saranas’ SAFE-MCS Trial Reaches Enrollment Midpoint

March 27, 2023—Saranas, Inc. announced that it has reached the midpoint for enrollment in the SAFE-MCS clinical trial.

SYNTAX Compares Quality-of-Life Results for PCI With DES and CABG

March 17, 2011—In the New England Journal of Medicine, David J. Cohen, MD, et al have published findings from the SYNTAX (Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial that investigated the quality-of-life effects of percutaneous coronary intervention (PCI) with the use of drug-eluting stents (2011;364:1016–1026). The SYNTAX study is sponsored by Boston Scientific Corporation (Natick, MA).

Medtronic’s Evolut TAVR Platform Studied in Analyses of 4-Year EVOLUT Low Risk Trial Data

March 11, 2024—Medtronic announced two late-breaking data presentations on 4-year outcomes from the EVOLUT Low Risk trial of the company’s Evolut transcatheter aortic valve replacement (TAVR) platform for the treatment of symptomatic severe aortic stenosis.

SPIRIT IV Results Published, Cost-Effectiveness Analysis Presented

May 5, 2010—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, et al have published findings from the SPIRIT IV trial in the New England Journal of Medicine (2010;362:1663–1674). Abbott Vascular also announced that David Cohen, MD, presented findings from a retrospective cost-effectiveness analysis of SPIRIT IV data on March 13 at the Cardiovascular Research Foundation's Optimizing PCI Outcomes symposium in Atlanta.

SPIRIT IV Safety and Efficacy Results Published and Cost-Effectiveness Analysis Presented

May 5, 2010—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, et al have published findings from the SPIRIT IV trial in the New England Journal of Medicine (2010;362:1663–1674). Abbott Vascular also announced that David Cohen, MD, presented findings from a retrospective cost-effectiveness analysis of SPIRIT IV data on March 13 at the Cardiovascular Research Foundation's Optimizing PCI Outcomes symposium in Atlanta.

Zoll’s TherOx SSO₂ Therapy Is Evaluated for Clinical Utility and Economic Value in Postmarket REAL SSO₂ Study

January 17, 2023—Zoll Medical Corporation, an Asahi Kasei company, announced that the first patient has been enrolled in the REAL SSO2 postmarket study assessing the clinical utility and cost-effectiveness of the company’s TherOx supersaturated oxygen (SSO2) therapy used after percutaneous coronary intervention (PCI) compared to PCI alone in standard-of-care treatment for ST-elevation myocardial infarction (STEMI) patients.